+Compare
ARWR
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
3.21B

ARWR Price Prediction, Arrowhead Pharmaceuticals AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ARWR Trading results, last 6 months
AI Robots NameP/L
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EST Dec 09, 2022

ARWR's Indicator enters downward trend

The Aroon Indicator for ARWR entered a downward trend on December 08, 2022. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 182 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 182 cases the stock moved lower. This puts the odds of a downward move at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where ARWR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

ARWR moved below its 50-day moving average on December 08, 2022 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARWR crossed bearishly below the 50-day moving average on November 15, 2022. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 01, 2022. You may want to consider a long position or call options on ARWR as a result. In of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ARWR just turned positive on December 01, 2022. Looking at past instances where ARWR's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in of 341 cases, the price rose further within the following month. The odds of a continued upward trend are .

ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ARWR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.045) is normal, around the industry mean (22.071). P/E Ratio (0.000) is within average values for comparable stocks, (73.843). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.816). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (13.106) is also within normal values, averaging (313.855).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published Earnings

ARWR is expected to report earnings to fall 88.44% to -9 cents per share on February 09

Arrowhead Pharmaceuticals ARWR Stock Earnings Reports
Q4'22
Est.
$-0.09
Q3'22
Missed
by $0.22
Q2'22
Missed
by $0.11
Q1'22
Beat
by $0.27
Q4'21
Missed
by $0.15
The last earnings report on November 28 showed earnings per share of -80 cents, missing the estimate of -58 cents. With 771.15K shares outstanding, the current market capitalization sits at 3.21B.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 1.89B. The market cap for tickers in the group ranges from 401 to 285.45B. NONOF holds the highest valuation in this group at 285.45B. The lowest valued company is CDXI at 401.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -4%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 173%. AMAM experienced the highest price growth at 808%, while GOSS experienced the biggest fall at -76%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -37%. For the same stocks of the Industry, the average monthly volume growth was -66% and the average quarterly volume growth was -80%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: 24 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
177 E. Colorado Boulevard
Phone
+1 626 304-3400
Employees
397
Web
https://www.arrowheadpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
RQI12.490.07
+0.60%
COHEN & STEERS QUALITY Income REALTY FUND
TINY30.69N/A
N/A
ProShares Nanotechnology ETF
ENTR9.40N/A
N/A
ERShares Entrepreneur ETF
MFUS38.89-0.12
-0.31%
PIMCO RAFI Dyn Multi-Factor US Eq ETF
GBAB16.15-0.26
-1.58%
Guggenheim Taxable Municipal

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been closely correlated with FATE. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARWR jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-4.18%
FATE - ARWR
79%
Closely correlated
-1.15%
VXRT - ARWR
77%
Closely correlated
-9.65%
EDIT - ARWR
77%
Closely correlated
-5.31%
RCKT - ARWR
76%
Closely correlated
+2.15%
ALEC - ARWR
76%
Closely correlated
-0.58%
More